Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02155829 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD)
A Phase 1 study, sponsored by Uniformed Services University of the Health Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT02155829: Completed Phase 1 study, sponsored by Uniformed Services University of the Health Sciences.
NCT02155829 is a Phase 1 study that has completed, run by Uniformed Services University of the Health Sciences. The registered enrollment target is 75 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02155829, a Phase 1 study, has completed, sponsored by Uniformed Services University of the Health Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Riluzole is effective in the augmentation treatment of post-traumatic stress disorder (PTSD) that is experienced by Active Duty military service members and Operation Enduring Freedom (OEF), Operation Iraqi Freedom (OIF), and Operation New Dawn (OND) veterans who have not had symptom reduction after one or more kinds of medications or therapies.
Primary Outcome
CAPS is a 30-item structured interview that can be used to make current (past month) diagnoses of PTSD, make lifetime diagnoses of PTSD, and assess PTSD symptoms over the past week. A summed score of 17 items: Minimum Score: 0 (no symptoms) Maximum Score: 136 (very severe symptoms) Subscales: Subscale B (re-experiencing): items 1-5, a score of 0-40. Subscale C (avoidance): items 6-12, a score of 0-56. Subscale D (hyperarousal): items 13-17, a score of 0-40. CAPS scores were measured at bas
Interventions
- DRUG Riluzole
- DRUG Placebo (for Riluzole)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2013-07 |
| Est. Completion | 2017-11-30 |
| Phase | Phase 1 |
What the finished NCT02155829 record still lists
NCT02155829 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% higher).
The record links to 0 conditions, and to 2 interventions - of which Riluzole is the first listed.
NCT02155829 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02155829 about?
NCT02155829 is a clinical study titled "Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD)". The purpose of this study is to determine whether Riluzole is effective in the augmentation treatment of post-traumatic stress disorder (PTSD) that is experienced by Active Duty military service members and Operation Enduring Freedom (OEF), Operation Iraqi Freedom (OIF), and Operation New Dawn (OND)...
What is the current status of trial NCT02155829?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2013-07. Estimated completion is 2017-11-30.
What interventions are being tested in trial NCT02155829?
The interventions under investigation include: Riluzole (DRUG), Placebo (for Riluzole) (DRUG).
Who is sponsoring clinical trial NCT02155829?
This trial is sponsored by Uniformed Services University of the Health Sciences, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02155829's enrollment target sits among peer trials
75 711th of 2000 higher than 1,276 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia